Home → Deep Dives → GENI Q2 Review: What the Screener Found, and What the Business Proved

GENI Q2 Review: What the Screener Found, and What the Business Proved

GENI Constructive — the gate is GAAP, not the platform
Since publish GENI -25.7% GENI: $7.59 → $5.64 as of 2026-09-19

The full review lives at /deep-dives/geni-q2-review/.

This is the post-earnings follow-up to the 25 June thesis, published at $5.83. Q2 2026 reported 6 August: revenue $195.5M against a $185M guide, adjusted EBITDA $52.6M against $45M, and full-year guidance raised on both lines.

Five tabs: the scorecard of what was called against what printed, the Legend revenue back-out, the GAAP-positivity gate that keeps the multiple suppressed, a valuation of the Polymarket and Kalshi agreements, and the revised price target.

the terminal I use
referral link

Godel Terminal

A browser-based research terminal with a Bloomberg-style command interface: DES, FOCUS, TAS, HDS. Real-time quotes, filings, financials, ownership and news, at $996 a year against Bloomberg's roughly $27,000.

I use it for the filing and ownership work behind the deep dives, the part that used to mean six browser tabs and a spreadsheet. It handles research and analysis; order execution and dealer chat are not in it, so it sits alongside a broker rather than replacing one. There is a 14-day trial, so the cheapest way to judge it is to run it against whatever you use now.

Godel Terminal showing GANX: description, float and institutional ownership, valuation ratios, price chart, and a live news and filings feed
GANX in Godel: float, insider and institutional ownership, valuation ratios and the filings feed on one screen. That name is a position in The Book.
Try Godel Terminal → code mungbeans · 30% off your first month

The rest of what I pay for →

Disclosure: this is a referral link and mungbeans.io earns a commission if you subscribe, at no extra cost to you. The discount code is why it is here; the recommendation is because I pay for it myself. The site carries no advertising, and every paid link is listed on one page.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.